The global porcine vaccines market was valued at US$ 1,784.0 Mn in
2016 and is projected to expand at a compounded annual growth rate
(CAGR) of 7.0% from 2017 to 2025, according to a new report published
by Transparency Market Research (TMR) titled “Porcine Vaccines
Market: Global Industry Analysis, Size, Share, Growth, Trends, and
Forecast, 2017–2025.” The report suggests that increase in the
number of hog/swine farms and rise in the demand for porcine meat and
gelatin are expected to drive the global porcine vaccines market from
2017 to 2025. North America and Europe are projected to dominate the
global market during the forecast period, owing to increase in the
demand for swine meat and high adoption of porcine vaccines for
instant treatment planning by veterinary doctors as well as
researchers. The market in Asia Pacific is projected to expand at a
rapid CAGR during the forecast period. Growth of the market in Asia
Pacific can be attributed to large volume of pig cultivation in
countries of Southeast Asia, rising population of pigs requiring
treatment for various diseases such as diarrhea and swine influenza,
and growth of biotechnology firms producing swine vaccines in the
region. The market for porcine vaccines in Latin America is likely to
expand at a moderate growth rate during the forecast period.
Report Overview @
https://www.prnewswire.com/news-releases/porcine-vaccines-market-to-reach-us-3208-mn-by-2025-says-tmr-679503443.html
The global porcine vaccines market is projected to be driven by
value-added features offered by various animal health care companies
in order to streamline the day-to-day workflow and increase the
revenue. Porcine vaccines provide a wide range of benefits for the
treatment of swine diseases. Key players offering porcine vaccines
are coming up with vaccines with value-added features such as
effective recombinant vaccines, DNA vaccines, and conjugate vaccines.
These new features or technological advancements in vaccines reduce
the overall vaccination cost and thus, improve the overall
effectiveness and efficiency of swine production practices. Companies
are focusing on the development of vaccines for major diseases such
as African swine flu and porcine circovirus associated disease
(PCVAD). Other factors such as growth of biotechnology companies
engaged in research and development of porcine vaccines, rise in
investments in R&D, and growing government initiatives for
funding societies for growth of the agriculture field are fueling the
global porcine vaccines market.
Among technologies, the inactivated vaccines segment is anticipated
to hold a prominent market share by 2025. The segment is projected to
witness growth during the forecast period, due to easy availability,
low risk of revert reaction of killed viruses among swine, low cost,
and new innovations by key players. The live attenuated vaccines
segment is estimated to hold a major market share by the end of 2017,
due to increase in broader cross-protective immunity. The segment is
likely to be driven by increase in the occurrence of new virus
strains of PCVAD or PRRSV and chances of reverse reaction of
vaccination, which can infect healthy swine and can spread to the
herd. Live attenuated vaccines facilitate outcomes in the treatment
of classical swine fever (CSF). Increase in major losses in pig
farming due to CSF is likely to fuel the segment during the forecast
period.
The report offers detailed segmentation of the global porcine
vaccines market, by disease indication. Based on disease indication,
the market has been segmented into diarrhea, swine influenza,
arthritis, Bordetella rhinitis, porcine reproductive and respiratory
syndrome (PRRS), porcine circovirus associated disease (PCVAD), and
others (CHRS, leptospirosis, etc.). Diarrhea and porcine circovirus
associated disease (PCVAD) segments are poised to account for a
significant share of the market during the forecast period. Factors
responsible for higher share held by diarrhea and porcine circovirus
associated disease (PCVAD) segments include rising incidence of
climatic changes, overfeeding of protein diet, and ingestion of
microscopic parasites along with food. Various funding and awareness
programs by government and private animal health care organizations
for treating swine diseases have resulted in significant shares held
by diarrhea and porcine circovirus associated disease (PCVAD)
segments in the global market.
Request for Sample Copy of Report @
Among end-users, the hog production farms segment accounted for a
leading share of the global porcine vaccines market in 2016 and is
estimated to gain market share by 2025. It is projected to expand at
a CAGR of more than 7% during the forecast period. Expansion of
specialized pig production units in major countries worldwide and
increasing demand for pork meat and byproducts such as gelatin have
led to prominent share held by the hog production farms segment in
the global porcine vaccines market. Increasing pork trading and
growing number of pig slaughterhouses with the rising demand for pork
meat are likely to drive the hog production farms segment during the
forecast period. High prevalence and incidence rates of swine
diseases in farms have resulted in increased visits by farmers to
veterinary hospitals. These factors are expected to fuel the
veterinary hospitals segment between 2017 and 2025.
North America and Europe accounted for a significant share of the
global porcine vaccines market in 2016 and are likely to gain market
share by 2025. High consumption of pork meat and high production of
swine have contributed to leading share held by these regions in the
global porcine vaccines market. Asia Pacific is projected to be the
most attractive market for porcine vaccines by 2025, with the highest
attractiveness index. The market in Asia Pacific is projected to
expand at a high CAGR of nearly 8% during the forecast period, due to
increasing trading of pork meat in developing countries such as India
and China. Rising number of production units for hog/swine and high
consumption of pork meat in countries such as Japan, Australia, New
Zealand, Malaysia, Singapore, and Taiwan are likely to fuel the Asia
Pacific porcine vaccines market from 2017 to 2025. The market in
Latin America is poised to expand at a moderate growth rate during
the forecast period, due to increasing production of pigs in
Argentina and increased government funding for R&D in Brazil.
The report also provides profiles of leading players operating in the
global porcine vaccines market. Boehringer Ingelheim GmbH, Ceva Santé
Animale, Elanco (Eli Lilly and Company), Merck & Co., Inc., and
Zoetis, Inc. are some of the leading players operating in the market,
which account for a significant market share. Companies operating in
the market are aiming to enhance their geographical presence through
strategic acquisitions and collaborations with leading players in the
respective domain and geography. In January 2015, Elanco (Eli Lilly)
completed the acquisition of Novartis Animal Health (Novartis AH) for
US$ 5.28 Bn. The acquisition has provided Elanco with greater
commercial presence in the companion animals & swine sector.
Other prominent players operating in the global porcine vaccines
market are Bimeda Animal Health, Vetoquinol, and Bayer AG.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=42440
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment